{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T21:13:44Z","timestamp":1778706824354,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.intimp.2017.11.043","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T20:03:11Z","timestamp":1512504191000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Telbivudine attenuates UUO-induced renal fibrosis via TGF-\u03b2\/Smad and NF-\u03baB signaling"],"prefix":"10.1016","volume":"55","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2017.11.043_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.6970.1","article-title":"Recent advances in understanding of chronic kidney disease","volume":"4","author":"Yamaguchi","year":"2015","journal-title":"F1000Res"},{"key":"10.1016\/j.intimp.2017.11.043_bb0010","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2017.11.043_bb0015","series-title":"In Vivo","first-page":"1","article-title":"Pathophysiological mechanisms of renal fibrosis:a review of animal models and therapeutic strategies","volume":"vol. 31","author":"Nogueira","year":"2017"},{"key":"10.1016\/j.intimp.2017.11.043_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9498013","article-title":"Matrix metalloproteinases and subclinical atherosclerosis in chronic kidney disease: a systematic review","author":"Kousios","year":"2016","journal-title":"Int. J. Nephrol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40139-013-0025-8","article-title":"Myofibroblasts in fibrotic kidneys","volume":"1","author":"Nakagawa","year":"2013","journal-title":"Curr. Pathobiol. Rep."},{"key":"10.1016\/j.intimp.2017.11.043_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00441-011-1275-6","article-title":"Role of TGF-\u03b2 in chronic kidney disease: an integration of tubular, glomerular and vascular effects","volume":"347","author":"L\u00f3pez-Hern\u00e1ndez","year":"2012","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.intimp.2017.11.043_bb0035","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s11255-015-1115-9","article-title":"Role of Smad signaling in kidney disease","volume":"47","author":"Zhang","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0040","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.7150\/ijbs.7.1056","article-title":"Diverse roles of TGF-\u03b2\/Smads in renal fibrosis and inflammation","volume":"7","author":"Lan","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2017.11.043_bb0045","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneph.2014.114","article-title":"Inflammatory processes in renal fibrosis","volume":"10","author":"Meng","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3109\/08923973.2015.1127382","article-title":"TGF-\u03b2: the connecting link between nephropathy and fibrosis","volume":"38","author":"Sutariya","year":"2016","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0055","doi-asserted-by":"crossref","first-page":"F861","DOI":"10.1152\/ajprenal.00362.2001","article-title":"Obstructive nephropathy and renal fibrosis","volume":"283","author":"Klahr","year":"2002","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.trsl.2014.07.010","article-title":"Therapeutic targets for treating fibrotic kidney diseases","volume":"165","author":"Lee","year":"2015","journal-title":"Transl. Res."},{"key":"10.1016\/j.intimp.2017.11.043_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/jvh.12059","article-title":"Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients","volume":"20","author":"Wang","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.intimp.2017.11.043_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000000646","article-title":"Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B","volume":"94","author":"Qi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.intimp.2017.11.043_bb0075","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.12217","article-title":"Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy","volume":"21","author":"Lee","year":"2014","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.intimp.2017.11.043_bb0080","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3109\/00365521.2014.962604","article-title":"Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study","volume":"49","author":"Lin","year":"2014","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0085","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2013.09.031","article-title":"Telbivudine improves renal function in patients with chronic hepatitis B","volume":"146","author":"Gane","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2017.11.043_bb0090","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.15074","article-title":"Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates","volume":"14","author":"Liang","year":"2014","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.intimp.2017.11.043_bb0095","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.intimp.2017.11.043_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MEG.0000000000000519","article-title":"Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B","volume":"28","author":"Law","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0105","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijantimicag.2017.01.015","article-title":"Telbivudine attenuates gentamicin-induced kidney injury in rats","volume":"49","author":"Kader","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.intimp.2017.11.043_bb0110","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/ki.2009.86","article-title":"Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy","volume":"75","author":"Chevalier","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.intimp.2017.11.043_bb0115","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1128\/AAC.00029-08","article-title":"Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B","volume":"52","author":"Bridges","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2017.11.043_bb0120","first-page":"1761","article-title":"HuangQi decoction ameliorates renal fibrosis via TGF-\u03b2\/Smad signaling pathway in vivo and in vitro, cell Physiol","volume":"38","author":"Zhao","year":"2016","journal-title":"Biochemist"},{"key":"10.1016\/j.intimp.2017.11.043_bb0125","doi-asserted-by":"crossref","first-page":"O90","DOI":"10.1111\/1469-0691.12220","article-title":"A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study","volume":"20","author":"Tsai","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.intimp.2017.11.043_bb0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cyto.2016.08.019","article-title":"The cellular and signalling alterations conducted by TGF-\u03b2 contributing to renal fibrosis","volume":"88","author":"Vega","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2017.11.043_bb0135","first-page":"C216","article-title":"Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis","volume":"304","author":"Zeisberg","year":"2013","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.intimp.2017.11.043_bb0140","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/liv.12589","article-title":"Telbivudine therapy may shape CD4(+) T-cell response to prevent liver fibrosis in patients with chronic hepatitis B","volume":"35","author":"Li","year":"2015","journal-title":"Liver Int."},{"key":"10.1016\/j.intimp.2017.11.043_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1746-1596-7-141","article-title":"Expression of MMP-2 and TIMP-1in renal tissue of patients with chronic active antibody-mediated renal graft rejection","volume":"7","author":"Yan","year":"2012","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0150","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1210\/en.2010-0286","article-title":"Antifibrotic properties of Relaxin: in vivo mechanism of action in experimental renal Tubulointerstitial fibrosis","volume":"151","author":"Hewitson","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.intimp.2017.11.043_bb0155","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","article-title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry","volume":"92","author":"Visse","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.intimp.2017.11.043_bb0160","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s11033-012-2186-7","article-title":"Overexpressed C-, type natriuretic peptide serves as an early compensatory response to counteract extracellular matrix remodeling in unilateral ureteral obstruction rats","volume":"40","author":"Hu","year":"2013","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.intimp.2017.11.043_bb0165","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/labinvest.2012.68","article-title":"Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy","volume":"92","author":"Du","year":"2012","journal-title":"Lab. Investig."},{"key":"10.1016\/j.intimp.2017.11.043_bb0170","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.3892\/mmr.2013.1391","article-title":"Amygdalin inhibits renal fibrosis in chronic kidney disease","volume":"7","author":"Guo","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.intimp.2017.11.043_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphys.2015.00082","article-title":"TGF-\u03b2\/Smad signaling in renal fibrosis","volume":"6","author":"Meng","year":"2015","journal-title":"Front. Physiol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8319283","article-title":"TGF-\u03b21\/Smads and miR-21 in renal fibrosis and inflammation","volume":"2016","author":"Loboda","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.intimp.2017.11.043_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated Smad signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0190","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/etm.2016.3152","article-title":"Astragalus Membranaceus ameliorates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro","volume":"11","author":"Shan","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2017.11.043_bb0195","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/596829","article-title":"Heptitis Bvirus infection and the kidney:renal abnormalities in HBV patients,antiviral drugs handling,and specific follow-up","author":"Deray","year":"2015","journal-title":"Adv. Hepatol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0200","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/ndt\/17.3.363","article-title":"The inflammatory component in progressive renal disease-are interventions possible?","volume":"17","author":"Noronha","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.intimp.2017.11.043_bb0205","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.ASN.0000130564.75008.F5","article-title":"Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction","volume":"15","author":"Esteban","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00430-014-0370-1","article-title":"Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection","volume":"204","author":"Zhang","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0215","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00705-012-1508-3","article-title":"The role of the toll-like receptor TLR4 in hepatitis B virus-associated glomerulonephritis","volume":"158","author":"Zhou","year":"2012","journal-title":"Arch. Virol."},{"key":"10.1016\/j.intimp.2017.11.043_bb0220","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.phymed.2016.01.013","article-title":"Elsholtzia Ciliata (Thunb.) Hylander attenuates renal inflammation and interstitial fibrosis via regulation of TGF-\u00df and Smad3 expression on unilateral ureteral obstruction rat model","volume":"23","author":"Kim","year":"2016","journal-title":"Phytomedicine"},{"key":"10.1016\/j.intimp.2017.11.043_bb0225","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ncpneph0098","article-title":"Obstructive nephropathy: towards biomarker discovery and gene therapy","volume":"2","author":"Chevalier","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576917304630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:08:41Z","timestamp":1761584921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576917304630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":45,"alternative-id":["S1567576917304630"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.043","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Telbivudine attenuates UUO-induced renal fibrosis via TGF-\u03b2\/Smad and NF-\u03baB signaling","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2017.11.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}